Noile-Immune Biotech Inc.
Stock Price Chart
2026/10/02 18:47 UpdatedPrice Trend
2026/10/02 18:47 UpdatedPrice & Trading Details
2026/10/02 18:47 UpdatedPRICE
TRADING
Analyst Recommendations 1 analysts
Updated 2026/10/01Earnings Calendar
Updated 2026/10/01Recent Earnings
| Date | EPS Est. | EPS Actual | Surprise |
|---|---|---|---|
| 2026/08/12 | ¥-5.51 | ¥-5.05 | +8.4% |
| 2026/05/13 | ¥-5.05 | ¥-3.54 | +29.9% |
| 2026/02/12 | ¥-5.42 | ¥-4.36 | +19.6% |
| 2025/11/12 | ¥-11.04 | ¥-4.46 | +59.6% |
Shareholder Composition
Updated 2026/10/01Financial Performance
2026/10/04 UpdatedRevenue & Profit
Margins
Cash Flow
Financial Health
| 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | ¥626M | ¥317M | ¥8M | ¥5M |
| Gross Profit | ¥619M | ¥315M | ¥7M | ¥5M |
| Operating Income | -¥106M | -¥775M | -¥1,069M | -¥797M |
| Pretax Income | -¥106M | -¥775M | -¥1,069M | -¥797M |
| Net Income | -¥387M | -¥1,130M | -¥964M | -¥794M |
| EPS | -¥9.87 | -¥27.25 | -¥22.28 | -¥18.33 |
| Operating Margin | -16.99% | -244.74% | -14,092.29% | -15,945.08% |
| Balance Sheet | ||||
| Total Assets | ¥4,641M | ¥5,779M | ¥4,800M | ¥4,012M |
| Total Equity | ¥4,301M | ¥5,687M | ¥4,725M | ¥3,932M |
| Total Liabilities | ¥340M | ¥91M | ¥75M | ¥80M |
| Cash | ¥4,521M | ¥5,556M | ¥4,671M | ¥3,918M |
| Interest-bearing Debt | - | - | - | - |
| Equity Ratio | 92.67% | 98.42% | 98.44% | 98.01% |
| D/E Ratio | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Flow | ||||
| Operating CF | -¥107M | -¥873M | -¥888M | -¥752M |
| Investing CF | - | -¥5M | ¥1M | -¥0M |
| Financing CF | ¥488M | ¥1,913M | ¥3M | -¥0M |
| Free CF | -¥107M | -¥873M | -¥888M | -¥752M |
| Efficiency | ||||
| ROE | -8.99% | -19.87% | -20.41% | -20.18% |
| ROA | -8.33% | -19.55% | -20.09% | -19.78% |
Latest IR Information
-
Notice of Completion of Payment for the Issuance of Noile-Immune Biotech Inc. 14th Stock Acquisition Rights (with Exercise Price Adjustment Clause) by Third-Party Allotment
Announcement of issuance by third-party allotment and completion of payment for the 14th stock acquisition rights. Total subscription amount is 1,400,000 yen, potential shares amount to 10,000,000 shares, and terms including the adjusted reference price and lock-up are specified.
Read more -
Notice of Issuance of the 14th Series of New Share Subscription Rights (with Exercise Price Adjustment Clause) to Nol Immunoon Biotechnology Corporation through Third-Party Allotment
1) Funding amount is 1,349 million yen (total paid-in amount 1,361.4 million yen, net proceeds rough 1,349.4 million yen) 2) Potential shares: 10,000,000 shares, initial exercise price 136 yen, lower limit 81 yen, exercise price linked to a adjustment clause...
Read more
Latest News (5 items)
-
Average Analyst Rating: none
Average Target Price: ¥440
Rating Score: - (Based on 1 analysts)
※1=Strong Buy, 5=Strong Sell
Company Information
About
Noile-Immune Biotech Inc. researches and develops CAR-T cells for novel cancer immunotherapies. The company's product pipeline includes, NIB101, a target antigen for solid tumors; NIB102, a next-generation CAR-T cell therapy; NIB103, autologous CAR-T cell therapy for mesothelin (MSLN); NIB104, a PRIME technology against target antigens in solid tumors; ADAP01; AUTL01; and CHUG01. Noile-Immune Biotech Inc. was incorporated in 2015 and is headquartered in Minato, Japan.
